Answers are grounded in this paper and cite their sources.
Comparison of PD-1 inhibitors reveals superior survival outcomes in specific subgroups, indicating personalized treatment potential.
Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1-positive subgroups, suggesting biomarker-driven therapeutic selection. These findings underscore the importance of PD-L1 status in optimizing immunotherapy regimens for advanced NSCLC, offering clinical insights for personalized treatment strategies.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: